Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor–Positive Breast Cancer: A Multicohort Study

Abstract
Radiogenomic signatures associated with genomic assays (Oncotype DX) were identified as independent predictors after adjusting for clinical factors for survival and neoadjuvant chemotherapy response in estrogen receptor–positive breast cancer.

Citation
Fan, M., Cui, Y., You, C., Liu, L., Gu, Y., Peng, W., … Li, L. (2021). Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor–Positive Breast Cancer: A Multicohort Study. Radiology. doi:10.1148/radiol.2021210738

Publisher
Radiological Society of North America (RSNA)

Journal
Radiology

DOI
10.1148/radiol.2021210738

Additional Links
http://pubs.rsna.org/doi/10.1148/radiol.2021210738

Permanent link to this record